Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

Key myelodysplastic syndrome pipeline therapies in various stages of development include MBG453, Tamibarotene, CA-4948, RVU120, TQB2618, AMG 176, SAR443579, Etavopivat, AG-946, Venetoclax ...

Updated data from the BEXMAB study reveals a significant increase in complete remission rates for patients with high-risk ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

Delivers Second-Quarter Net Revenues of $15.423 Billion, an Increase of 6.6 Percent on a Reported Basis or 6.5 Percent on an Operational Basis "AbbVie delivered another outstanding quarter with strong ...

Q2 2025 Earnings Call Transcript August 5, 2025 Rigel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Few patients with MDS receive treatment with hypomethylating agents, with evidence of age-, sex-, and race-related disparities.

Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with ...

The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition considered incurable without transplantation, according to a new clinical ...